Ropinirole treatment for restless legs syndrome

M. Molnár, Katalin Fornadi, Colin M. Shapiro

Research output: Contribution to journalArticle

Abstract

In this paper we discuss therapy with ropinirole (known as adartrel in the United Kingdom) in patients with restless legs syndrome. Restless legs syndrome is characterized by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. Current recommendations suggest dopaminergic therapy (levodopa or dopamine receptor agonists like ropinirole) as the first-line treatment for restless legs syndrome. Based on the results of randomized, placebo-controlled, double-blind trials, we conclude that ropinirole is effective in reducing symptoms of restless legs syndrome in the general population. Ropinirole has no serious or common side effects that would limit its use significantly. Rebound and augmentation problems are relatively rarely seen with ropinirole, although properly designed comparative trials are still needed to address this question. It must be noted, however, that most published studies with ropinirole compare this drug with placebo. Very few studies have compared ropinirole with other drugs (L-dopa, gabapentin, opioids, benzodiazepines, other dopaminergic agents and selegiline hydrochloride). No cost-effectiveness trial has been published yet. Treatment of restless legs syndrome with ropinirole shows it to be effective, well-tolerated and safe and it can be used in restless legs syndrome in general.

Original languageEnglish
Pages (from-to)587-598
Number of pages12
JournalDrugs of Today
Volume42
Issue number9
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Restless Legs Syndrome
Therapeutics
Leg
Placebos
Selegiline
Dopamine Agents
ropinirole
Dopamine Agonists
Levodopa
Benzodiazepines
Pharmaceutical Preparations
Opioid Analgesics
Cost-Benefit Analysis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Ropinirole treatment for restless legs syndrome. / Molnár, M.; Fornadi, Katalin; Shapiro, Colin M.

In: Drugs of Today, Vol. 42, No. 9, 09.2006, p. 587-598.

Research output: Contribution to journalArticle

Molnár, M. ; Fornadi, Katalin ; Shapiro, Colin M. / Ropinirole treatment for restless legs syndrome. In: Drugs of Today. 2006 ; Vol. 42, No. 9. pp. 587-598.
@article{3b2ff7dd6b1f40ad916944d2925cf6f5,
title = "Ropinirole treatment for restless legs syndrome",
abstract = "In this paper we discuss therapy with ropinirole (known as adartrel in the United Kingdom) in patients with restless legs syndrome. Restless legs syndrome is characterized by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. Current recommendations suggest dopaminergic therapy (levodopa or dopamine receptor agonists like ropinirole) as the first-line treatment for restless legs syndrome. Based on the results of randomized, placebo-controlled, double-blind trials, we conclude that ropinirole is effective in reducing symptoms of restless legs syndrome in the general population. Ropinirole has no serious or common side effects that would limit its use significantly. Rebound and augmentation problems are relatively rarely seen with ropinirole, although properly designed comparative trials are still needed to address this question. It must be noted, however, that most published studies with ropinirole compare this drug with placebo. Very few studies have compared ropinirole with other drugs (L-dopa, gabapentin, opioids, benzodiazepines, other dopaminergic agents and selegiline hydrochloride). No cost-effectiveness trial has been published yet. Treatment of restless legs syndrome with ropinirole shows it to be effective, well-tolerated and safe and it can be used in restless legs syndrome in general.",
author = "M. Moln{\'a}r and Katalin Fornadi and Shapiro, {Colin M.}",
year = "2006",
month = "9",
doi = "10.1358/dot.2006.42.9.996568",
language = "English",
volume = "42",
pages = "587--598",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - Ropinirole treatment for restless legs syndrome

AU - Molnár, M.

AU - Fornadi, Katalin

AU - Shapiro, Colin M.

PY - 2006/9

Y1 - 2006/9

N2 - In this paper we discuss therapy with ropinirole (known as adartrel in the United Kingdom) in patients with restless legs syndrome. Restless legs syndrome is characterized by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. Current recommendations suggest dopaminergic therapy (levodopa or dopamine receptor agonists like ropinirole) as the first-line treatment for restless legs syndrome. Based on the results of randomized, placebo-controlled, double-blind trials, we conclude that ropinirole is effective in reducing symptoms of restless legs syndrome in the general population. Ropinirole has no serious or common side effects that would limit its use significantly. Rebound and augmentation problems are relatively rarely seen with ropinirole, although properly designed comparative trials are still needed to address this question. It must be noted, however, that most published studies with ropinirole compare this drug with placebo. Very few studies have compared ropinirole with other drugs (L-dopa, gabapentin, opioids, benzodiazepines, other dopaminergic agents and selegiline hydrochloride). No cost-effectiveness trial has been published yet. Treatment of restless legs syndrome with ropinirole shows it to be effective, well-tolerated and safe and it can be used in restless legs syndrome in general.

AB - In this paper we discuss therapy with ropinirole (known as adartrel in the United Kingdom) in patients with restless legs syndrome. Restless legs syndrome is characterized by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. Current recommendations suggest dopaminergic therapy (levodopa or dopamine receptor agonists like ropinirole) as the first-line treatment for restless legs syndrome. Based on the results of randomized, placebo-controlled, double-blind trials, we conclude that ropinirole is effective in reducing symptoms of restless legs syndrome in the general population. Ropinirole has no serious or common side effects that would limit its use significantly. Rebound and augmentation problems are relatively rarely seen with ropinirole, although properly designed comparative trials are still needed to address this question. It must be noted, however, that most published studies with ropinirole compare this drug with placebo. Very few studies have compared ropinirole with other drugs (L-dopa, gabapentin, opioids, benzodiazepines, other dopaminergic agents and selegiline hydrochloride). No cost-effectiveness trial has been published yet. Treatment of restless legs syndrome with ropinirole shows it to be effective, well-tolerated and safe and it can be used in restless legs syndrome in general.

UR - http://www.scopus.com/inward/record.url?scp=33750143506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750143506&partnerID=8YFLogxK

U2 - 10.1358/dot.2006.42.9.996568

DO - 10.1358/dot.2006.42.9.996568

M3 - Article

C2 - 17028668

AN - SCOPUS:33750143506

VL - 42

SP - 587

EP - 598

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 9

ER -